Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
STERIS plc (NYSE: STE) is a leading global provider of infection prevention and procedural surgical products and services, primarily serving healthcare, pharmaceutical, research, and medical device customers. With a mission to create a healthier today and a safer tomorrow, the company delivers innovative infection prevention, decontamination, and health science technologies that support patient care and safety.
Founded in 1985 as Innovative Medical Technologies and rebranded as STERIS in 1987, the company’s history traces back to 1894 with the American Sterilizer Company, a pioneer in sterilization products. Today, STERIS is headquartered in Dublin, Ireland, and has positioned itself as a formidable force in the industry through strategic acquisitions and continuous innovation.
STERIS operates through several segments:
- Healthcare Services: Constituting approximately 70% of total revenue, this segment includes sterilizers, washer-disinfectors, and other decontamination equipment for healthcare facilities and biopharmaceutical manufacturing sites.
- Applied Sterilization Technologies (AST): Generating 19% of revenue, AST provides contract sterilization services for single-use and implantable medical devices globally.
- Life Sciences Services: Accounting for about 11% of revenue, this segment offers services and products for research and pharmaceutical environments.
In recent developments, STERIS has signed a definitive agreement to acquire surgical and sterilization assets from Becton, Dickinson and Company (BD) for $540 million. This acquisition, expected to close by September 2023, will expand STERIS’s product offerings within its Healthcare segment, focusing on operating rooms and sterile processing departments.
Financially, STERIS has demonstrated robust growth. For the first quarter of fiscal 2024, revenue increased by 11% to $1.28 billion, driven by improvements in procedure volumes and easing of supply chain challenges. The company continues to show strength across its segments, particularly in Healthcare, which saw a 17% growth in revenue to $818.9 million.
Moreover, STERIS is undergoing a targeted restructuring plan in its Healthcare surgical business in Europe, aiming to enhance its operational efficiency. This includes product rationalizations and facility consolidations, signaling a commitment to long-term profitability and growth.
STERIS remains committed to its vision of creating a safer world through continuous innovation and strategic expansions, making it a key player in the global healthcare industry.
STERIS expects to finalize the acquisition of Cantel Medical by June 2, 2021, pending a shareholder vote on April 29, 2021. For fiscal 2021, the company reported a revenue increase of approximately 3%, totaling $3.1 billion, and an anticipated income from operations of about $548 million. Additionally, adjusted income is projected at $699 million, with free cash flow around $447 million. The effective tax rate is expected between 19-20%. Comprehensive results will be shared in an earnings call on May 19, 2021.
Cantel Medical Corp. (NYSE: CMD) reported its second quarter financial results for 2021, achieving net sales of $294.0M, up 1.9% year-over-year. Despite the pandemic's ongoing impact on elective procedures, GAAP earnings per diluted share rose to $0.27, compared to a loss of $(0.05) a year prior. Non-GAAP EPS increased by 29.5% to $0.79, driven by strong demand in dental and medical segments. The company has reduced its debt by $175.0M and ended the quarter with $243.1M in cash and gross debt of $988.4M, indicating solid financial health amidst challenges.
STERIS plc (NYSE: STE) announced the planned resignation of CEO Walt Rosebrough, effective July 29, 2021. Chief Operating Officer Dan Carestio will succeed him. Rosebrough will transition to a role as CEO Emeritus and Senior Advisor for two years. Under Rosebrough's leadership, STERIS achieved significant milestones, including tripling revenue and completing nearly 50 acquisitions, resulting in a market capitalization increase of over $14 billion. The Board expressed confidence in Carestio's leadership skills and successful integration of various business segments.
STERIS plc (NYSE: STE) announced a conference call to discuss its fiscal 2021 third quarter financial results on February 3, 2021, at 10:00 a.m. ET. Interested parties can join via phone or listen live online. A detailed press release will follow after market close on February 2, 2021. This call aims to provide insights into STERIS's financial performance and outlook. The company emphasizes its mission to create a healthier world through innovative healthcare solutions.
STERIS has announced its acquisition of Cantel Medical Corp for approximately $3.6 billion, valuing Cantel shares at $84.66. The deal includes expected synergies of $110 million by the fourth year and is aimed at enhancing STERIS's offerings in infection prevention, particularly in endoscopy and dental markets. The transaction is anticipated to close by the end of STERIS's first fiscal quarter of 2022, pending regulatory approvals. This acquisition positions STERIS strongly in a market focused on infection control, leveraging Cantel's existing infrastructure and customer base.
STERIS plc (NYSE: STE) will webcast presentations by CEO Walt Rosebrough at two upcoming investor conferences. The first is at 3:30 p.m. ET on January 11, 2021, during the Needham & Company Healthcare Conference, followed by the J.P. Morgan Healthcare Conference at 7:30 a.m. ET on January 13, 2021. The presentations will be accessible at steris-ir.com for thirty days. Furthermore, the company plans to announce its third-quarter fiscal 2021 results on February 2, followed by an investor call on February 3.
STERIS plc has completed its acquisition of Key Surgical, enhancing its product offerings and global reach. The acquisition is expected to generate approximately $55 million in revenue and $0.13 in adjusted earnings per diluted share for fiscal 2021, surpassing initial estimates by 35%. STERIS aims to leverage Key Surgical's capabilities to improve customer service and create shareholder value. Goldman Sachs served as the financial advisor for STERIS, while Piper Sandler advised Key Surgical.
STERIS plc (NYSE: STE) reported a 3% increase in revenue for Q2 fiscal 2021, totaling $756.1 million, with a 2% rise in constant currency organic revenue. Net income rose to $105.9 million, or $1.23 per diluted share, and adjusted net income reached $127.3 million, or $1.48 per diluted share. Significant growth was observed in the Applied Sterilization Technologies and Life Sciences segments, which posted increases of 11% and 17% respectively. The company announced a quarterly dividend of $0.40 per share, payable on December 18, 2020.
STERIS plc (NYSE: STE) will hold a conference call on November 3, 2020, at 10:00 a.m. ET to discuss its fiscal 2021 Q2 financial results. A press release detailing these results will be issued after market close on November 2, 2020. The call can be accessed via www.steris-ir.com or by phone at 1-833-535-2199 (U.S.) or 1-412-902-6776 (international). A replay will be available after the call. STERIS aims to provide innovative healthcare solutions globally, ensuring safety and health in various environments.
STERIS plc (NYSE: STE) has signed an agreement to acquire Key Surgical for $850 million, expected to close by December 31, 2020. This strategic purchase aims to enhance STERIS's consumable product portfolio, particularly in sterile processing, operating rooms, and endoscopy. Key Surgical is projected to generate approximately $170 million in annual revenue with an adjusted EBIT of about $50 million in 2020. The acquisition is anticipated to yield annualized pre-tax earnings synergies of $10-$15 million by year three and will be accretive to STERIS’s earnings in the fiscal 2021 fourth quarter.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
What does STERIS plc specialize in?
Where is STERIS plc headquartered?
What are the main business segments of STERIS plc?
How much of STERIS’s revenue comes from Healthcare Services?
What recent acquisition has STERIS plc announced?
What was STERIS’s revenue growth in the first quarter of fiscal 2024?
What is the anticipated revenue growth for fiscal 2024?
What restructuring efforts is STERIS undertaking?
What percentage of STERIS’s revenue is derived from Applied Sterilization Technologies (AST)?
When was STERIS plc originally founded?
